CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.
CG Oncology by the Numbers
Based on preliminary clinical data presented at SUO annual meeting 2023, Phase 3 BOND-003 study of cretostimogene grenadenorepvec in monotherapy for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC):
of patients evaluable for efficacy (n=50/66) have achieved complete response (CR) at any time.
of patients evaluable for efficacy (n=42/66) have achieved complete response (CR) at the 6-month landmark assessment.
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
IRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc. today announced that Phase 3 monotherapy data from the BOND-003 clinical trial evaluating the efficacy and safety of cretostimogene grenadenorepvec in patients with high-risk NonMuscle Invasive Bladder Cancer (NMIBC)...
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023
IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. announced today that interim Phase 3 monotherapy data from the BOND-003 study will be presented as a late-breaking abstract at the upcoming 24th Annual Meeting of the Society of Urologic Oncology (SUO), held November...
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
Company appoints Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer With decades of proven experience, they bring leadership to successfully lead...